Considering the relationship between UGT1A1 polymorphisms, increased toxicities, and subsequent therapy discontinuation, it raises the possibility that pharmacogenomics may play a role in the adverse outcomes experienced by African American women with breast cancer. The gene discussed is UGT1A1; the disease is breast carcinoma.